Therapeutic Goods Administration raises oversight fears

“The prolonged therapeutic use of ‘unapproved’ medicinal cannabis products, especially in the vulnerable paediatric population calls into question the appropriateness of the TGA to continue to place the risk of prescribing of these products with the medical profession whilst an unregulated industry continues to grow…” the document reads.

“There is little scrutiny on whether the risk-benefit ratio remains favourable over time for patients who use them. This concern is especially…